Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Susan Sloan

Nurse Practitioner Science Hill, KY Nurse Practitioner

NPI 1134508880 CMS profile 10953354

5775 N Highway 27 Ste 6, Science Hill, KY 42553

Open in the dashboard

General payments

$5,794

445 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Susan Sloan of Science Hill, KY is reported in the CMS Open Payments database as having received $5,794 across 445 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $943 71
2024 General $1,210 97
2023 General $1,488 112
2022 General $1,214 97
2021 General $939 68

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Susan Sloan
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Susan Sloan were reported at $943. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Susan Sloan Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $939 $135 $40–$426 $132
2022 $1,214 $152 $48–$470 $149
2023 $1,488 $166 $54–$529 $160
2024 $1,210 $173 $55–$556 $164
2025 $943 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Otsuka America Pharmaceutical, Inc. $728 86 payments
  2. AbbVie, Inc. $634 49 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $598 65 payments
  4. Novo Nordisk Inc $489 41 payments
  5. Lilly USA, LLC $297 21 payments
  6. Pfizer Inc. $284 27 payments
  7. Ironshore Pharmaceuticals Inc. $275 15 payments
  8. Astellas Pharma US Inc $223 5 payments
  9. AstraZeneca Pharmaceuticals LP $219 13 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $177 10 payments
  11. Other $1,872 113 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,609 443 payments
  2. Education $185 2 payments
Products named General payments · program years 2021–2025
  1. REXULTI $728 86 payments
  2. XIFAXAN $598 65 payments
  3. Ozempic $388 34 payments
  4. RYBELSUS $388 34 payments
  5. VRAYLAR $275 16 payments
  6. NURTEC ODT $234 24 payments
  7. UBRELVY $232 22 payments
  8. JORNAY PM $210 11 payments
  9. ZAVZPRET $192 21 payments
  10. Kerendia $177 10 payments
  11. Other $3,557 231 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 139 drugs

Part D claims

7,798

Median for Nurse Practitioner: 389

Drug cost

$681,051

Median for Nurse Practitioner: $21,885

Branded share of claims

22.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 148 $167,439
Jardiance Empagliflozin Brand 117 $96,492
Ozempic Semaglutide Brand 84 $84,409
Eliquis Apixaban Brand 59 $38,773
Farxiga Dapagliflozin Propanediol Brand 48 $30,291
Linzess Linaclotide Brand 35 $22,257
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 25 $20,624
Januvia Sitagliptin Phosphate Brand 16 $20,386
Trulance Plecanatide Brand 24 $18,354
Breo Ellipta Fluticasone/Vilanterol Brand 38 $15,294

The 10 drugs with the highest cost, of 139 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $246
  • Lundbeck LLC $18
$265 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $87
$87 — —
VRAYLAR
  • AbbVie, Inc. $80
$80 — —
NURTEC ODT
  • PFIZER INC. $78
$78 14 —
ZAVZPRET
  • PFIZER INC. $73
$73 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

445 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record